血清CA153、CA125、CA199和CEA联合检测在乳腺癌诊断中的价值

目的探讨联合检测血清CA153、CA125、CA199和CEA的含量对乳腺癌的诊断价值。方法运用电化学发光免疫分析方法检测乳腺癌68例、乳腺良性疾病50例及体检健康女性58名血清中CA153、CA125、CA199、CEA的含量，分析各肿瘤标志物诊断的灵敏度、特异度、准确度及联合检测的临床意义。结果单独检测CA153、CA125、CA199、CEA对乳腺癌诊断的阳性率分别为76．4％（52／68）、44．1％（30／68）、35．3％（24／68）、29．4％（20／68）；联合检测4种肿瘤标志物的阳性率为94．1％（64／68）。结论血清CA153、CA125、CA199和CEA联合检测具有提高乳腺癌早期诊断的价值。

Clinical value of combined detection of serum CA153, CA125, CA199 and CEA in breast cancer diagnosis

Objective To investigate the clinical value of combined measure of the serum levels of CA153, CA125, CA199 and CEA in the diagnosis of breast cancer. Methods Serum levels of CA153, CA125, CA199 and CEA in 68 patients with breast cancer, 50 patients with benign breast diseases and 58 healthy volunteers were measured by electrochemiluminescence immunoassay （ECLIA）. Results The levels of CA153, CA125, CA199 and CEA in breast cancer group were significantly higher than those in benign breast disease and healthy volunteers. Sensitivities of CA153, CA125, CA199 and CEA were 76.4 % （52/68）, 44.1% （30/68）, 35.3 % （24/68）, 29.4 % （20/68）, respectively. The positive rate of combination of tumor markers was 94.1% （64/68）. Conclusion The combined assay of CA153, CA125, CA199 and CEA can improve the early diagnostic rate of breast cancer.